Navigation Links
PDL BioPharma Announces Fourth Quarter and Full Year 2012 Financial Results
Date:3/1/2013

INCLINE VILLAGE, Nev., March 1, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2012.

(Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

Total revenues in 2012 were $374.5 million, compared to $362.0 million in 2011, with royalty revenues increasing seven percent over full year 2011. For the fourth quarter of 2012, total revenues were $86.0 million, compared to $72.8 million in the fourth quarter of 2011.

Royalty revenues for the fourth quarter of 2012 are based on third quarter product sales by PDL's licensees. The fourth quarter 2012 revenue growth was primarily driven by increased royalties from third quarter 2012 sales of Herceptin® and Avastin®, which are marketed by Genentech and Roche.  Royalty revenue for the fourth quarter and 2012 are net of payments made under our February 2011 settlement agreement with Novartis Pharma AG.

Operating expenses in 2012 were $25.5 million, compared with $18.3 million in 2011. For the fourth quarter of 2012, general and administrative expenses were $7.7 million compared with $4.8 million for the same period of 2011.

Net income in 2012 was $211.7 million, or $1.45 per diluted share as compared with net income of $199.4 million in 2011 or $1.15 per diluted share. Net income for the fourth quarter of 2012 was $49.4 million or $0.34 per diluted share as compared with net income of $38.9 million or $0.24 per diluted share for the same period of 2011.

Net cash provided by operating activities in 2012 was $210.2 million, compared with $169.8 million in 2011. At December 31, 2012, PDL had cash, cash equivalents and investments of $148.7 million, compared with $227.9 million at
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
2. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
5. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
7. S1 Biopharma Expands Focus to Include Male Sexual Health
8. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
9. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
10. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  ConvaTec, a privately-held ... Nigel Clerkin has been appointed chief financial officer ... Mr. Clerkin was previously executive vice president and chief ... -based biotechnology company.  Mr. Clerkin was part of ... at Elan, culminating in its sale to Perrigo, a ...
(Date:7/22/2014)... 22, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... R&D outsourcing company with operations in China ... announced that it will release financial results for the second ... on Wednesday, August 13, 2014 (which will be Thursday morning, ... available on the investor relations section of the Company,s website ...
(Date:7/22/2014)... , July 22, 2014  According to the ... their children spend on digital devices. An AOA survey ... of 10 and 17 estimate they use an electronic ... a separate AOA survey of parents revealed that only ... electronic device for that same amount of time. Eye ...
Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4
... Medicated Arthri-Zen Relief Cream(R) Clinically Shown to Work for up ... Americans suffer from the aches and pains that come with ... effective ways to get fast relief from arthritis pain is ... the relief tends to be short-lived. Many people find that ...
... economic slowdown, America,s pharmaceutical research and biotechnology companies ... the research and development of new life-changing medicines ... billion from 2007, according to analyses by the ... Burrill & Company. PhRMA-member companies alone invested ...
Cached Medicine Technology:Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain 2Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain 3R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 3R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges 4
(Date:7/22/2014)... DocbookMD , a HIPAA-secure mobile communication company, ... largest physician-centric mobile communication solutions in Texas at Memorial ... Created by Austin-based physicians, Tracey Haas, D.O., MPH, and ... into MHMD’s Accountable Care Network to enhance communication between ... put this capability at the fingertips of our physicians ...
(Date:7/22/2014)... Air Conditioning & Heating Inc. is ... Daikin comfort pro dealer. This means that the company ... cooling system equipment. Only a select few businesses have ... being approved. , Daikin co-developed an R-410A refrigerant with ... Air Conditioning Market. They are also the inventor of ...
(Date:7/22/2014)... IN (PRWEB) July 22, 2014 United ... advisory organization, announces that Les McPhearson, an insurance veteran ... as CEO effective immediately and be based in the ... said, "I am delighted that Les chose to accept ... perfectly qualified to address the many challenges facing UBA ...
(Date:7/22/2014)... Steven Reinberg HealthDay Reporter ... obese during pregnancy may be more likely to have children ... "We found that, compared with children born from mothers of ... pregnancy had up to 20 to 30 percent higher odds ... professor of pediatrics at Children,s Hospital of Pittsburgh. Forno,s ...
(Date:7/22/2014)... the Clean Plate Club you eat pretty much everything ... A new Cornell University study shows that the average adult ... or her plate. "If you put it on ... Ph.D., author of the forthcoming book, Slim by Design, Professor ... Lab. , Wansink and co-author Katherine Abowd Johnson analyzed 1179 ...
Breaking Medicine News(10 mins):Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 2Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 3Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 4Health News:Air Conditioning & Heating Inc. Now an Authorized Daikin Comfort Pro Dealer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 3
... showing its worth in soft-tissue repair, says one Singapore doctor. , ... ... surgeons about 15 years ago to enhance wound healing of bone grafts ... today being applied in Singapore as an alternative to the conventional mode ...
... just about every online weight loss program available, picked them ... about the best ones.PHOENIX, April 13 Member Authority set ... three goals: lose weight fast, keep the pounds off, and ... each program based on those same three factors, plus filled ...
... Cambridge Research & Instrumentation, Inc. (CRi) was presented ... Technologies in Drug Discovery Product Line Strategy Award ... Life Sciences award banquet.The Award recognizes CRi,s product ... markets, achieved by creating innovative solutions that address ...
... Enhancing the effects of the drug used to treat ... leukemia (CML) are first treated with a drug known ... progresses it often becomes resistant to the drug. However, ... United Kingdom, and Thomas Jefferson University, Philadelphia, has identified ...
... ChoiceEAGAN, Minn., April 13 Blue Cross and Blue ... array of individual health plan options available in the ... their own. The new plans were designed with input ... own health plan" sessions, in which prospective individual buyers ...
... won,t use findings, survey suggests , , MONDAY, April ... practicing clinicians in the United States aren,t aware ... complementary and alternative (CAM) therapies, a new survey ... acupuncturists, naturopaths, internists and rheumatologists, also found that ...
Cached Medicine News:Health News:Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries 2Health News:Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries 3Health News:Singapore First in Southeast Asia to Use Novel Treatment for Sports and Musculoskeletal Injuries 4Health News:Online Diets Reviewed: Your Top 4 Metabolism Boosting, Fat Burning Plans 2Health News:Online Diets Reviewed: Your Top 4 Metabolism Boosting, Fat Burning Plans 3Health News:Frost & Sullivan Recognizes CRi for Innovations Leading to Personalized Medicine 2Health News:JCI online early table of contents: April 13, 2009 2Health News:JCI online early table of contents: April 13, 2009 3Health News:JCI online early table of contents: April 13, 2009 4Health News:JCI online early table of contents: April 13, 2009 5Health News:JCI online early table of contents: April 13, 2009 6Health News:Blue Cross Launches Largest Selection of Individual Plans Available in Minnesota 2Health News:Blue Cross Launches Largest Selection of Individual Plans Available in Minnesota 3Health News:Awareness of Alternative Therapies May Be Lacking 2
... This is an enzyme immunoassay(EIA) ... antibodies to extractable nuclear antigens Sm, ... in human serum. The results from ... an aid in the diagnosis of ...
... designed with the proper sensitivity and specificity ... of autoimmune disease. Sera from over 2,000 ... individuals were tested during the development of ... compared the results to reference methods such ...
The K-ASSAY Rheumatoid Factor Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assay for quantifying...
Total IgE Control...
Medicine Products: